Headlines about Arca Biopharma (NASDAQ:ABIO) have been trending somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Arca Biopharma earned a news sentiment score of 0.07 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 44.9938627072616 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of Arca Biopharma (NASDAQ:ABIO) traded up $0.01 during trading hours on Wednesday, reaching $1.78. The company’s stock had a trading volume of 80,029 shares, compared to its average volume of 539,383. Arca Biopharma has a fifty-two week low of $1.05 and a fifty-two week high of $2.85. The stock has a market capitalization of $20.86, a PE ratio of -0.93 and a beta of 1.90.
Arca Biopharma (NASDAQ:ABIO) last posted its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter.
ARCA biopharma, Inc (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF).
Receive News & Ratings for Arca Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arca Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.